Skip to main content

Table 1 Summary and comparison of APAP-induced effects in age-matched fasted and nonfasted male CD-1 mice and Z-VAD.fmk (10 mg/kg) pretreated fed mice (APAP 530 mg/kg; 5h and 24 h).a

From: RETRACTED ARTICLE: Diet Restriction Inhibits Apoptosis and HMGB1 Oxidation and Promotes Inflammatory Cell Recruitment during Acetaminophen Hepatotoxicity

  Fed control Fed APAP Fast control Fast APAP Fed Z-VAD.fmk Fed APAP + Z-VAD.fmk
5 h after dose
Irreversible binding, nmol/mg 1.87 (0.45) 1.95 (0.44) 1.82 (0.64)
Hepatic ATP, nmol/mg 35.5 (4.0) 5.2 (2.1)c 17.1 (5.3) 2.3 (1.0)c 37.4 (6.1) 3.1 (1.4)c
Hepatic GSH, nmol/mg 70.6 (10.6) 9.6 (5.1)c 42.6 (5.9) 3.6 (1.8)c 63.2 (12.5) 15.3 (7.8)c
Serum total HMGB1, ng/mL 7.4 (5.2) 210.2 (55.1)c 20.1 (6.3) 295.8 (20.3)d, e 2.5 (5.4) 301.9 (24.0)d, e
Hypoacetylated HMGB1, fold increment N/D 17.4 (2.3)d N/D 24.1 (5.1)d, e N/D 27.3 (3.4)d, e
Hyperacetylated HMGB1, fold increment N/D 1.4 (0.2)b N/D 1.6 (0.4)b N/D 2.1 (0.4)b
Serum K18 fragments, pmol/mL 126.2 (25.1) 801.4 (198.1)b 176.7 (62.3) 232.4 (201.6)e 107.8 (40.3) 164.9 (78.4)e
Serum full-length K18, pmol/mL 6.5 (2.4) 15,246.1 (804.3)d 8.9 (4.5) 19,057.5 (1024.7)d, f 7.1 (2.4) 23,614.0 (1237.2)d, f
Serum ALT activity, U/L 78.2 (65.4) 2,146.4 (1012.3)b 49.8 (27.5) 2,048.6 (461.7)c 35.8 (10.5) 3,607.0 (782.1)c, e
Serum TNF-α, pg/mL 51.4 (12.4) 62.1 (13.5) 57.1 (13.0) 101.2 (40.1) 68.1 (22.1) 60.4 (7.8)
Serum IL-6, pg/mL 25.4 (6.7) 54.3 (10.2)b 23.1 (4.0) 35.4 (10.5)e 34.0 (9.8) 50.4 (18.4)
24 h after dose
Irreversible binding, nmol/mg   
Hepatic ATP, nmol/mg 33.1 (2.1) 27.4 (6.6) 16.4 (3.7) 5.1 (2.0)c, f 37.4 (7.1) 31.5 (3.9)
Hepatic GSH, nmol/mg 65.4 (10.7) 58.3 (5.9) 39.7 (6.3) 22.5 (8.5)b, e 73.8 (15.9) 47.9 (10.1)b, e
Serum total HMGB1, ng/mL 10.2 (7.4) 17.5 (5.5) 15.4 (3.5) 353.1 (28.6)d, g 4.7 (3.1) 429.5 (42.0)d, g
Hypoacetylated HMGB1, fold increment N/D N/D N/D 33.6 (5.8)d N/D 35.6 (4.7)d
Hyperacetylated HMGB1, fold increment N/D 1.7 (0.3) N/D 14.9 (4.2)c, f N/D 17.2 (3.2)c, f
Serum K18 fragments, pmol/mL 102.6 (35.1) 914.0 (103.2)b 150.1 (21.5) 160.4 (42.9)e 183.4 (71.0) 162.2 (39.2)e
Serum full-length K18, pmol/mL 5.4 (1.2) 17,610.0 (1599.5)d 13.6 (6.9) 26,721.6 (3853.0)d, f 10.3 (5.8) 30,016.6 (2128.6)d, f
Serum ALT activity, U/L 27.5 (5.7) 2,654.5 (334.5)c 63.2 (22.5) 3,603.8 (508.8)c, e 50.2 (11.2) 4,891.6 (701.2)c, f
Serum TNF-α, pg/mL 45.8 (6.4) 95.0b (14.1) 63.1 (19.7) 227.8 (53.6) c, f 54.7 (16.1) 262.2 (39.7) d, f
Serum IL-6, pg/mL 30.1 (2.0) 203.0 (39.6) c 27.5 (12.6) 96.4 (35.2)b, f 26.6 (3.3) 100.8 (28.1)b, f
  1. aData are given as mean ± SD of six mice per group carried out in three independent investigations. Statistical significance was assigned relative to vehicle and fed matched control status at that time point (bP < 0.05, cP < 0.01 and dP< 0.005) and between fasted and Z-VAD.fmk-pretreated APAP dosed mice (530 mg/mg) with fed APAP-treated mice (530 mg/mg) (eP < 0.05, fP< 0.01 and gP< 0.005). N/D, not detected.
\